Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

FBIO

Fortress Biotech Inc

Feb 11 • 04:00PM ET

3.67

-0.08 -2.13 %

Healthcare • Biotechnology • USA • NASD

Peers: BMRN FOLD PTGX XENE MGTX TGTX QURE ANAB CRSP EDIT

| Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-0.27	Insider Own	20.29%	Shs Outstand	31.01M	Perf Week	19.16%
Market Cap	113.91M	Forward P/E	367.00	EPS next Y	0.01	Insider Trans	0.00%	Shs Float	24.74M	Perf Month	-12.62%
Enterprise Value	105.30M	PEG	-	EPS next Q	0.11	Inst Own	14.84%	Short Float	18.53%	Perf Quarter	41.70%
Income	-5.34M	P/S	1.83	EPS this Y	111.71%	Inst Trans	-1.79%	Short Ratio	6.23	Perf Half Y	82.59%
Sales	62.30M	P/B	2.04	EPS next Y	-96.83%	ROA	2.58%	Short Interest	4.58M	Perf YTD	0.27%
Book/sh	1.80	P/C	1.32	EPS next 5Y	-	ROE	10.35%	52W High	4.53 -18.98%	Perf Year	114.62%
Cash/sh	2.78	P/FCF	-	EPS past 3/5Y	39.06% 24.49%	ROIC	-4.59%	52W Low	1.33 176.98%	Perf 3Y	-67.81%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-5.71% 9.50%	Gross Margin	60.21%	Volatility	9.62% 8.06%	Perf 5Y	-93.42%
Dividend TTM	-	EV/Sales	1.69	EPS Y/Y TTM	94.05%	Oper. Margin	-149.18%	ATR (14)	0.27	Perf 10Y	-90.80%
Dividend Ex-Date	-	Quick Ratio	1.97	Sales Y/Y TTM	-0.32%	Profit Margin	-8.57%	RSI (14)	56.22	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.19	EPS Q/Q	114.54%	SMA20	8.58%	Beta	1.39	Target Price	10.75
Payout	-	Debt/Eq	1.22	Sales Q/Q	20.52%	SMA50	6.79%	Rel Volume	0.73	Prev Close	3.75
Employees	101	LT Debt/Eq	1.08	Earnings	Nov 14 BMO	SMA200	39.73%	Avg Volume	736.20K	Price	3.67
IPO	Nov 17, 2011	Option/Short	Yes / Yes	EPS/Sales Surpr.	126.19% -16.12%	Trades		Volume	540,698	Change	-2.13%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-15-24	Resumed	ROTH MKM	Buy	$10
Aug-04-22	Initiated	Ladenburg Thalmann	Buy	$6
Oct-02-20	Initiated	The Benchmark Company	Buy	$9
Dec-18-19	Initiated	B. Riley FBR	Buy	$9
Feb-28-18	Initiated	B. Riley FBR, Inc.	Buy	$10
Jul-11-17	Initiated	Rodman & Renshaw	Buy	$11
Mar-22-17	Initiated	JMP Securities	Mkt Outperform
Oct-03-16	Initiated	ROTH Capital	Buy	$9

Feb-05-26 12:56PM	Cigna Q4 Earnings Beat Estimates on Higher Specialty Volumes (Zacks)
Jan-28-26 12:21PM	Elevance Health Q4 Earnings Beat Estimates on Increasing Premiums (Zacks)
Jan-21-26 01:29PM	Centene Expands Palliative Care Access in Ohio Through Tuesday Health (Zacks)
Jan-14-26 06:06AM	Fortress Biotech receives FDA approval for Zycubo to treat Menkes disease (Pharmaceutical Business Review) -15.90%
Jan-13-26 07:45AM	Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States (GlobeNewswire) -7.14%
08:00AM	Loading…
Dec-15-25 08:00AM	Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission (GlobeNewswire) +13.31%
Dec-10-25 08:30AM	Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology (GlobeNewswire)
Nov-14-25 09:40AM	Fortress Biotech (FBIO) Surpasses Q3 Earnings Estimates (Zacks) +5.22%
08:40AM	Fortress Biotech: Q3 Earnings Snapshot (Associated Press Finance)
08:30AM	Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-12-25 05:25PM	Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-10-25 08:15AM	Kamada (KMDA) Misses Q3 Earnings Estimates (Zacks)
Nov-06-25 05:45PM	Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-05-25 08:30AM	Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025 (GlobeNewswire)
05:15PM	Loading…
Nov-04-25 05:15PM	Ultragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Oct-30-25 08:15AM	Apellis Pharmaceuticals, Inc. (APLS) Q3 Earnings and Revenues Top Estimates (Zacks)
Oct-24-25 08:30AM	Journey Medical Corporation Reports Combined Emrosi (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference (GlobeNewswire)
Oct-21-25 08:30AM	Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout (GlobeNewswire)
Oct-08-25 08:30AM	Journey Medical Corporation to Participate in October 2025 Investor Conferences (GlobeNewswire)
Oct-01-25 08:05AM	Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing (GlobeNewswire) -30.72%
08:00AM	Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101 (GlobeNewswire)
Sep-03-25 08:30AM	Journey Medical Corporation to Participate in September 2025 Investor Conferences (GlobeNewswire)
Sep-02-25 08:30AM	Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) +15.50%
Aug-18-25 08:30AM	Journey Medical Corporation to Present at the Emerging Growth Conference (GlobeNewswire) +6.13%
Aug-14-25 05:55PM	Fortress Biotech (FBIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +8.16%
04:49PM	Fortress Biotech: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-12-25 04:01PM	Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-08-25 08:10AM	Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
06:25PM	Loading…
Aug-07-25 06:25PM	Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
08:30AM	Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11 (GlobeNewswire)
Aug-05-25 04:01PM	Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025 (GlobeNewswire)
Jul-14-25 08:50AM	Why Fast-paced Mover Fortress Biotech (FBIO) Is a Great Choice for Value Investors (Zacks)
08:30AM	Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi (GlobeNewswire)
Jul-10-25 09:19AM	Ultragenyx (RARE) Surges 5.1%: Is This an Indication of Further Gains? (Zacks)
Jun-24-25 08:30AM	Journey Medical to Join Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-20-25 08:30AM	Journey Medical Corporation Announces Emrosi Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference (GlobeNewswire)
Jun-19-25 08:50AM	Despite Fast-paced Momentum, Fortress Biotech (FBIO) Is Still a Bargain Stock (Zacks)
Jun-09-25 08:30AM	Journey Medical Corporation Announces Emrosi Featured on "The Balancing Act" Airing on Lifetime TV (GlobeNewswire) +6.50%
Jun-03-25 08:50AM	Fortress Biotech (FBIO) Is Attractively Priced Despite Fast-paced Momentum (Zacks)
May-30-25 10:47AM	Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics (GlobeNewswire)
May-16-25 05:50AM	New Strong Sell Stocks for May 16th (Zacks)
May-15-25 05:30PM	Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +7.23%
04:25PM	Fortress Biotech: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:15AM	Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-14-25 05:15PM	ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-13-25 05:20PM	Exelixis (EXEL) Surpasses Q1 Earnings and Revenue Estimates (Zacks) +5.45%
04:15PM	Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates (GlobeNewswire)
May-08-25 08:50AM	Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-07-25 04:01PM	Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025 (GlobeNewswire)
08:00AM	Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference (GlobeNewswire)
Apr-01-25 04:01PM	Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer (GlobeNewswire)
Mar-31-25 05:50PM	Fortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-28-25 08:30AM	Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates (GlobeNewswire) -6.94%
Mar-26-25 07:39PM	Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript (SeekingAlpha)
04:01PM	Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-25-25 09:04AM	Fortress Biotech Inc (FBIO) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Mar-24-25 08:30AM	Journey Medical Corporation Launches Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea (GlobeNewswire)
Mar-19-25 04:01PM	Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025 (GlobeNewswire)
Mar-17-25 08:55AM	Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform (GlobeNewswire)
Mar-14-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
Mar-12-25 08:30AM	Journey Medical Corporation to Participate in the 37th Annual ROTH Conference (GlobeNewswire)
Mar-09-25 10:06PM	Sun Pharma to Acquire Checkpoint Therapeutics (PR Newswire)
Mar-05-25 04:15PM	Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement (GlobeNewswire)
04:01PM	Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi (DFD-29) to Treat Rosacea (GlobeNewswire)
Mar-04-25 04:01PM	Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida (GlobeNewswire)
Feb-27-25 04:05PM	Mustang Bio Announces Sale of Fixed Assets and Exit of Facility (GlobeNewswire)
Feb-11-25 04:10PM	Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Feb-10-25 08:00AM	Mustang Bio Announces Closing of $8 Million Public Offering (GlobeNewswire)
Feb-06-25 07:00AM	Mustang Bio Announces Pricing of $8 Million Public Offering (GlobeNewswire)
Jan-28-25 08:41AM	Fortress Biotech announces first patient dosed in Phase 2 trial of Triplex (TipRanks)
07:21AM	Fortress doses first subject in Phase II CMV vaccine trial (Clinical Trials Arena)
Jan-27-25 08:30AM	Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT (GlobeNewswire)
Jan-23-25 08:30AM	Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea (GlobeNewswire)
Jan-14-25 08:00AM	Mustang Bio Announces Reverse Stock Split (GlobeNewswire)
Jan-07-25 06:59AM	FDA accepts Sentynls Menkes disease therapy NDA for priority review (Pharmaceutical Technology)
Jan-06-25 08:00AM	Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease (PR Newswire)
08:00AM	Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease (GlobeNewswire)
Dec-13-24 06:15PM	Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT (cosibelimab-ipdl) (GlobeNewswire)
Nov-14-24 05:04PM	Fortress Biotech: Q3 Earnings Snapshot (Associated Press Finance) -8.92%
04:10PM	Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:05PM	Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-12-24 04:30PM	Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates (GlobeNewswire)
04:01PM	Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:30AM	Mustang Bio Receives Positive Listing Determination from Nasdaq (GlobeNewswire)
Nov-07-24 08:30AM	Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma (GlobeNewswire)
Nov-04-24 07:00AM	Journey Medical Corporation Announces U.S. FDA Approval of Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea (GlobeNewswire) -8.95%
Oct-25-24 01:02PM	Highbridge Capital Management's Strategic Acquisition of Fortress Biotech Shares (GuruFocus.com) +6.94%
08:30AM	Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference (GlobeNewswire)
Oct-24-24 02:10PM	Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds (GlobeNewswire)
Oct-09-24 08:30AM	Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit (GlobeNewswire)
Oct-03-24 08:30AM	Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference (GlobeNewswire)
Sep-26-24 08:30AM	Fortress Biotech to Participate in October 2024 Investor Conferences (GlobeNewswire)
Sep-20-24 08:30AM	Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements (GlobeNewswire) -18.75%
Sep-16-24 07:30AM	Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024 (GlobeNewswire)
Sep-09-24 08:30AM	Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference (GlobeNewswire)

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fortress Biotech, Inc.	10% Owner	May 29 '25	Sale	1.29	100,000	129,000	6,122,249	Jun 03 06:34 PM

DERM Journey Medical Corp daily Stock Chart

Peers: EBS PTCT ANAB RVNC IRWD CAPR CDTX AVDL ATNM MNOV

| Held by: VTI IWM IWO VXF VTWO IWC VTWG QQQS RSSL OMFS

Index	RUT	P/E	-	EPS (ttm)	-0.37	Insider Own	47.49%	Shs Outstand	20.37M	Perf Week	-5.11%
Market Cap	265.72M	Forward P/E	31.64	EPS next Y	0.25	Insider Trans	0.00%	Shs Float	17.46M	Perf Month	3.23%
Enterprise Value	266.07M	PEG	-	EPS next Q	-0.05	Inst Own	26.07%	Short Float	14.66%	Perf Quarter	-10.73%
Income	-8.66M	P/S	4.47	EPS this Y	33.33%	Inst Trans	12.99%	Short Ratio	16.30	Perf Half Y	-6.44%
Sales	59.40M	P/B	8.14	EPS next Y	152.60%	ROA	-11.61%	Short Interest	2.56M	Perf YTD	3.63%
Book/sh	0.98	P/C	10.65	EPS next 5Y	-	ROE	-47.05%	52W High	9.56 -16.38%	Perf Year	56.97%
Cash/sh	0.75	P/FCF	-	EPS past 3/5Y	34.37% -	ROIC	-19.05%	52W Low	4.85 64.74%	Perf 3Y	280.48%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-3.84% 9.96%	Gross Margin	59.03%	Volatility	5.81% 7.04%	Perf 5Y	-
Dividend TTM	-	EV/Sales	4.48	EPS Y/Y TTM	60.26%	Oper. Margin	-16.92%	ATR (14)	0.50	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.12	Sales Y/Y TTM	2.82%	Profit Margin	-14.58%	RSI (14)	45.42	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.42	EPS Q/Q	20.27%	SMA20	-5.19%	Beta	0.82	Target Price	13.50
Payout	-	Debt/Eq	0.98	Sales Q/Q	20.52%	SMA50	-0.20%	Rel Volume	0.60	Prev Close	8.10
Employees	41	LT Debt/Eq	0.76	Earnings	Nov 12 AMC	SMA200	6.26%	Avg Volume	157.03K	Price	7.99
IPO	Nov 12, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-89.47% -6.54%	Trades		Volume	94,712	Change	-1.36%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-25-25	Initiated	H.C. Wainwright	Buy	$13
Jul-30-25	Resumed	B. Riley Securities	Buy	$12
Aug-22-24	Initiated	Rodman & Renshaw	Buy	$9
Jun-28-24	Resumed	ROTH MKM	Buy	$11
Dec-07-21	Initiated	B. Riley Securities	Buy	$14

Jan-08-26 02:00PM	Journey Medical (DERM) Publishes Positive Emrosi Phase 1 Microbiome Data (Insider Monkey)
Dec-10-25 08:30AM	Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology (GlobeNewswire) -5.29%
Nov-19-25 08:18AM	What Makes Journey Medical Corporation (DERM) a Good Investment? (Insider Monkey)
Nov-17-25 08:06PM	Journey Medical Corp (DERM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-12-25 06:30PM	Compared to Estimates, Journey Medical (DERM) Q3 Earnings: A Look at Key Metrics (Zacks) -15.31%
05:15PM	Loading…
05:15PM	Journey Medical Corporation (DERM) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-11-25 07:31AM	What To Expect From Journey Medical Corp (DERM) Q3 2025 Earnings (GuruFocus.com)
Nov-10-25 05:20PM	Guardian Pharmacy Services (GRDN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Nov-05-25 06:35PM	electroCore, Inc. (ECOR) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
08:30AM	Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025 (GlobeNewswire)
Nov-04-25 06:35PM	OmniAb, Inc. (OABI) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +5.63%
Oct-24-25 08:30AM	Journey Medical Corporation Reports Combined Emrosi (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference (GlobeNewswire)
Oct-08-25 08:30AM	Journey Medical Corporation to Participate in October 2025 Investor Conferences (GlobeNewswire)
Sep-22-25 09:03AM	Summers Value Partners' Update on Journey Medical (DERM) (Insider Monkey)
08:06AM	Loading…
Sep-04-25 08:06AM	New Strong Sell Stocks for September 4th (Zacks)
Sep-03-25 08:30AM	Journey Medical Corporation to Participate in September 2025 Investor Conferences (GlobeNewswire)
Aug-18-25 08:30AM	Journey Medical Corporation to Present at the Emerging Growth Conference (GlobeNewswire)
Aug-13-25 07:00PM	Journey Medical Corp (DERM) Q2 2025 Earnings Call Highlights: Strong Arosi Launch Drives ... (GuruFocus.com) -15.11%
Aug-12-25 05:15PM	Journey Medical Corporation (DERM) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +8.51%
04:01PM	Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-11-25 09:36AM	Journey Medical Corp (DERM) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
09:10AM	3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates (Zacks)
Aug-07-25 08:30AM	Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11 (GlobeNewswire)
Aug-05-25 04:01PM	Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025 (GlobeNewswire)
Aug-04-25 10:00AM	Journey Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-14-25 08:30AM	Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi (GlobeNewswire)
Jun-24-25 08:30AM	Journey Medical to Join Russell 2000 and Russell 3000 Indexes (GlobeNewswire) +8.93%
Jun-21-25 08:35AM	Journey Medical announces data analysis from Phase 3 trials of Emrosi (TipRanks)
Jun-20-25 08:30AM	Journey Medical Corporation Announces Emrosi Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference (GlobeNewswire)
08:30AM	Loading…
Jun-09-25 08:30AM	Journey Medical Corporation Announces Emrosi Featured on "The Balancing Act" Airing on Lifetime TV (GlobeNewswire)
May-15-25 07:01PM	Journey Medical Corp (DERM) Q1 2025 Earnings Call Highlights: Amrosi Launch Boosts Margins ... (GuruFocus.com) +18.93%
04:05PM	Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-14-25 05:10PM	Journey Medical Corporation (DERM) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -5.54%
04:01PM	Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-13-25 09:41AM	What To Expect From Journey Medical Corp (DERM) Q1 2025 Earnings (GuruFocus.com) -7.47%
May-12-25 07:10AM	Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
May-08-25 06:15PM	The Joint Corp. (JYNT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-07-25 04:01PM	Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025 (GlobeNewswire) +6.92%
May-06-25 05:20PM	Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -5.39%
May-05-25 09:57AM	Strength Seen in Profound Medical (PROF): Can Its 8.3% Jump Turn into More Strength? (Zacks)
Apr-30-25 05:25AM	Why Journey Medical Corporation (DERM) is Surging in 2025 (Insider Monkey)
Apr-23-25 07:00AM	Journey Medical (DERM) Moves 16.8% Higher: Will This Strength Last? (Zacks)
Apr-18-25 05:46PM	Is Journey Medical Corporation (DERM) a Cheap Hot Stock to Buy Right Now? (Insider Monkey)
Apr-07-25 09:17AM	Journey Medical (DERM) Surges 9.1%: Is This an Indication of Further Gains? (Zacks)
Apr-01-25 04:01PM	Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer (GlobeNewswire)
Mar-31-25 04:05PM	Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-27-25 08:25AM	Q4 2024 Journey Medical Corp Earnings Call (Thomson Reuters StreetEvents)
03:02AM	Journey Medical Corp (DERM) Q4 2024 Earnings Call Highlights: Strategic Launch of Emrosi and ... (GuruFocus.com)
Mar-26-25 07:10PM	Journey Medical Corporation (DERM) Q4 2024 Earnings Call Transcript (SeekingAlpha) -5.25%
05:15PM	Journey Medical Corporation (DERM) Tops Q4 Earnings Estimates (Zacks)
04:01PM	Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-25-25 09:04AM	Journey Medical Corp (DERM) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
08:50AM	Journey Medical launches Emrosi for the treatment of rosacea (TipRanks)
Mar-24-25 08:30AM	Journey Medical Corporation Launches Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea (GlobeNewswire) +13.94%
Mar-19-25 04:01PM	Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025 (GlobeNewswire) +7.88%
Mar-12-25 08:30AM	Journey Medical Corporation to Participate in the 37th Annual ROTH Conference (GlobeNewswire)
Mar-05-25 04:01PM	Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi (DFD-29) to Treat Rosacea (GlobeNewswire)
Mar-04-25 04:01PM	Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida (GlobeNewswire)
Feb-20-25 02:38PM	Journey Medical Corporation (DERM): A Bull Case Theory (Insider Monkey)
Jan-24-25 08:57AM	Minot Light Capitals Largest Performance Detractor in Q4: Journey Medical (DERM) (Insider Monkey) +8.05%
Jan-23-25 08:30AM	Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea (GlobeNewswire)
Nov-14-24 04:10PM	Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-12-24 05:25PM	Journey Medical Corporation (DERM) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -6.06%
04:01PM	Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-05-24 11:29AM	FDA approves Journey Medicals rosacea treatment Emrosi (Pharmaceutical Technology)
Nov-04-24 07:18AM	Journey Medical (DERM) Soars 7.3%: Is Further Upside Left in the Stock? (Zacks) -13.78%
07:00AM	Journey Medical Corporation Announces U.S. FDA Approval of Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea (GlobeNewswire)
Oct-25-24 08:30AM	Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference (GlobeNewswire) +6.27%
Oct-17-24 04:15PM	SWK Holdings Provides Portfolio Update (ACCESSWIRE)
Oct-03-24 08:30AM	Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference (GlobeNewswire)
Sep-09-24 08:30AM	Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference (GlobeNewswire)
Sep-04-24 08:15AM	Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-13-24 04:05PM	Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire) +14.22%
Aug-12-24 05:10PM	Journey Medical Corporation (DERM) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -15.26%
04:01PM	Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-06-24 04:01PM	Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024 (GlobeNewswire)
Jul-17-24 04:15PM	SWK Holdings Highlights Recent Achievements and Provides Portfolio Update (ACCESSWIRE)
Jul-11-24 04:05PM	Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors (GlobeNewswire)
May-15-24 04:15PM	Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:01PM	Journey Medical Corporation to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company Showcase (GlobeNewswire)
May-14-24 03:07AM	Journey Medical Corp (DERM) (Q1 2024) Earnings Call Transcript Highlights: Navigating Growth ... (GuruFocus.com)
May-13-24 08:55PM	DERM Stock Earnings: Journey Medical Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:01PM	Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-07-24 08:30AM	Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024 (GlobeNewswire)
May-01-24 04:01PM	Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer (GlobeNewswire)
Apr-29-24 09:00AM	Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
Apr-25-24 08:30AM	Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024 (GlobeNewswire)
Mar-28-24 04:05PM	Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) -5.40% -10.05%
Mar-25-24 07:01PM	Director Justin Smith Acquires 30,000 Shares of Journey Medical Corp (DERM) (GuruFocus.com) -11.52% +26.37%
Mar-22-24 06:01AM	Q4 2023 Journey Medical Corp Earnings Call (Thomson Reuters StreetEvents) -13.61%
Mar-21-24 09:53PM	DERM Stock Earnings: Journey Medical Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:01PM	Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-19-24 08:49AM	Journey Medical (DERM) Up as FDA Accepts Skin Disease Drug NDA (Zacks)
Mar-18-24 08:30AM	Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea (GlobeNewswire) +10.00%
Mar-15-24 08:30AM	Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024 (GlobeNewswire)
Mar-13-24 08:30AM	Journey Medical Corporation to Participate in the 36th Annual ROTH Conference (GlobeNewswire)
Mar-11-24 08:30AM	Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting (GlobeNewswire)
Feb-26-24 11:35AM	Journey Medical (DERM) to Report Q4 Earnings: What's in the Cards? (Zacks)
Jan-05-24 08:30AM	Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea (GlobeNewswire)

Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its brands include QBREXZA, Accutane, Targadox, AMZEEQ, Ximino, ZILXI, Exelderm, and Luxamend. The company was founded by Claude Maraoui in October 2014 and is headquartered in Scottsdale, AZ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Maraoui Claude	President & CEO	Aug 25 '25	Option Exercise	0.07	1,250,000	81,250	2,397,590	Aug 26 09:54 PM
Maraoui Claude	President & CEO	May 02 '25	Sale	6.84	4,834	33,065	2,348,313	May 05 05:34 PM
Benesch Joseph	CFO	May 02 '25	Sale	6.84	2,409	16,478	203,557	May 05 05:34 PM
Alloush Ramsey	COO	May 02 '25	Sale	6.84	2,857	19,542	504,817	May 05 05:31 PM
Maraoui Claude	President & CEO	Mar 11 '25	Sale	5.01	49,271	246,848	2,003,147	Mar 11 07:53 PM
Maraoui Claude	President & CEO	Mar 06 '25	Sale	5.04	25,551	128,777	2,067,323	Mar 10 06:21 PM
Maraoui Claude	President & CEO	Mar 07 '25	Sale	5.01	14,905	74,674	2,052,418	Mar 10 06:21 PM
Maraoui Claude	President & CEO	Mar 04 '25	Sale	5.04	28,901	145,661	2,111,021	Mar 05 07:53 PM
Maraoui Claude	President & CEO	Mar 03 '25	Sale	5.19	23,508	122,007	2,139,922	Mar 05 07:53 PM
Maraoui Claude	President & CEO	Mar 05 '25	Sale	5.13	18,147	93,094	2,092,874	Mar 05 07:53 PM
Benesch Joseph	CFO	Feb 21 '25	Sale	5.19	1,365	7,084	45,966	Feb 24 04:01 PM

FBIO

Fortress Biotech Inc

DERM

Journey Medical Corp

Upgrade your FINVIZ experience